SCM
MBX

Sterling Capital Management’s MBX Biosciences MBX Stock Holding History

Sterling Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02K Sell
109
-840
-89% -$29.3K ﹤0.01% 2513
2026
Q1 		$28.3K Sell
949
-692
-42% -$23.5K ﹤0.01% 1862
2025
Q4 		$51.8K Buy
1,641
+583
+55% +$14.1K ﹤0.01% 1790
2025
Q3 		$18.5K Buy
1,058
+598
+130% +$8K ﹤0.01% 2181
2025
Q2 		$5.25K Buy
460
+369
+405% +$3.76K ﹤0.01% 2483
2025
Q1 		$672 Sell
91
-70
-43% -$740 ﹤0.01% 2917
2024
Q4 		$2.97K Buy
+161
New +$3.43K ﹤0.01% 2649

Other funds holding MBX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Sterling Capital Management's MBX Position: Q2 2026 in Review

Sterling Capital Management reduced its MBX Biosciences (MBX) stake by 89% in Q2 2026, selling an estimated $29.3K and leaving 109 shares worth $6.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2513.

Sterling Capital Management first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. The position peaked at $51.8K in Q4 2025. 50 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Sterling Capital Management held 109 shares of MBX Biosciences worth $6.02K as of Q2 2026.
  • Sterling Capital Management sold 840 MBX Biosciences shares in Q2 2026, an estimated $29.3K.
  • MBX Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2513 holding.
  • Sterling Capital Management first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's MBX Biosciences position peaked at $51.8K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.